Navigation Links
Researchers find brain insulin plays critical role in the development of diabetes
Date:2/16/2011

Researchers from Mount Sinai School of Medicine have discovered a novel function of brain insulin, indicating that impaired brain insulin action may be the cause of the unrestrained lipolysis that initiates and worsens type 2 diabetes in humans. The research is published this month in the journal Cell Metabolism.

Led by Christoph Buettner, MD, Assistant Professor of Medicine in the Division of Endocrinology, Diabetes and Bone Disease at Mount Sinai School of Medicine, the research team first infused a tiny amount of insulin into the brains of rats and then assessed glucose and lipid metabolism in the whole body. In doing so, they found that brain insulin suppressed lipolysis, a process during which triglycerides in fat are broken down and fatty acids are released.

Furthermore, in mice that lacked the brain insulin receptor, lipolysis was unrestrained. While fatty acids are important energy sources during fasting, they can worsen diabetes, especially when they are released after the person has eaten, as happens in people with diabetes. Researchers previously believed that insulin's ability to suppress lipolysis was entirely mediated through insulin receptors expressed on adipocytes, or fat tissue cells.

"We knew that insulin has this fundamentally important ability of suppressing lipolysis, but the finding that this is mediated in a large part by the brain is surprising," said Dr. Buettner. "The major lipolysis-inducing pathway in our bodies is the sympathetic nervous system and here the studies showed that brain insulin reduces sympathetic nervous system activity in fat tissue. In patients who are obese or have diabetes, insulin fails to inhibit lipolysis and fatty acid levels are increased. The low-grade inflammation throughout the body's tissue that is commonly present in these conditions is believed to be mainly a consequence of these increased fatty acid levels."

Dr. Buettner added, "When brain insulin function is impaired, the release of fatty acids is increased. This induces inflammation, which can further worsen insulin resistance, the core defect in type 2 diabetes. Therefore, impaired brain insulin signaling can start a vicious cycle since inflammation can impair brain insulin signaling." This cycle is perpetuated and can lead to type 2 diabetes. Our research raises the possibility that enhancing brain insulin signaling could have therapeutic benefits with less danger of the major complication of insulin therapy, which is hypoglycemia."

Dr. Buettner's team plans to further study conditions that lead to diabetes such as overfeeding to test if excessive caloric intake impairs brain insulin function. A major second goal will be to find ways of improving brain insulin function that could break the vicious cycle by restraining lipolysis and improving insulin resistance. This study is supported by a grant from the National Institutes of Health and the American Diabetes Association. First author of the study is Thomas Scherer, PhD, postdoctoral fellow in the Department of Medicine in the Division of Endocrinology, Diabetes and Bone Disease.


'/>"/>

Contact: Mount Sinai Press Office
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related medicine news :

1. Financial planning a key but neglected component of Alzheimers care, say researchers
2. Researchers find reduced levels of an important neurotransmitter in MS
3. Homogeneous tuberculosis treatment ineffective in children, UT Southwestern researchers find
4. Researchers find public sector research responsible for many new drug discoveries
5. What makes fructose fattening? OHSU researchers find some answers in the brain
6. Researchers: Elderly patients 4 times more likely to die from treatment complications
7. Researchers identify the genotype of disorders causing cardiac sudden death syndrome
8. Researchers predict nearly 1.3 million cancer deaths in Europe in 2011
9. Researchers develop outline that may help weigh benefits of new imaging technologies
10. Project connects researchers, Latino communities to prevent cancer
11. Researchers get a grip on nervous systems receptors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... Somnoware, a leading provider ... care management module. Using this new feature, sleep physicians can now predict the ... continuous positive airway pressure (CPAP), oral, or other forms of sleep apnea therapy. ...
(Date:4/25/2017)... ... ... Vetoquinol USA® , a world-class developer of veterinarian-approved ... EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin UCII ... The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and joints. ...
(Date:4/24/2017)... ... April 24, 2017 , ... LG ... Your Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s national ... which pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use kit ...
(Date:4/24/2017)... ... April 24, 2017 , ... Ridgecrest Herbals makes it a point ... strategies to reduce waste, and support renewable energy. They believe this is a crucial ... to find solutions for health issues, and maintain that destroying the environment in the ...
(Date:4/24/2017)... TX (PRWEB) , ... April 24, 2017 , ... The ... the glitterati, those unreal icons inhabiting the rarified air of pop and film stardom.(1) ... paparazzi and anyone snapping pictures: the smile. Grins now run the gamut from being ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... Tenn. and DALLAS , April 19, 2017 ... announced that the first patients in Nashville ... device in the Lower Esophageal Sphincter Stimulation for GERD ... implantable device designed to provide long-term reflux control by ... GERD affects nearly 65 million people in ...
(Date:4/19/2017)... SAN DIEGO , April 19, 2017 /PRNewswire/ ... ("Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new ... today announced the closing of its previously announced ... common stock at a public offering price of ... commissions and estimated offering expenses payable by Sorrento.  ...
(Date:4/19/2017)... 2017  New research provides evidence that an old drug ... a study released today that will be presented at the ... Boston , April 22 to 28, 2017. ... Parkinson,s disease, the oral drug levodopa has long been considered ... as the disease progresses, the effects of the medication can ...
Breaking Medicine Technology: